Thrombolytic therapy is an important treatment for thrombosis, a life-threatening condition in
cardiovascular diseases. However, the traditional thrombolytic therapies have often been …

Low-toxicity magnetic nanocarriers (MNCs) composed of a shell of poly [aniline-co-N-(1-one-
butyric acid) aniline] over a Fe3O4 magnetic nanoparticle core were developed to carry …

Mortality and disabilities as outcomes of cardiovascular diseases are primarily related to
blood clotting. Optimization of thrombolytic drugs is aimed at the prevention of side effects (in …

We investigated the feasibility and efficacy of target thrombolysis with recombinant tissue
plasminogen activator (rtPA) covalently bound to magnetic nanoparticle (MNP) and retained …

Implant-assisted targeting of magnetic particles under the influence of an external magnetic
field has previously been verified through mathematical modeling, in vitro studies, and in …

Targeted delivery of thrombolytic drug to the site of emboli exhibits potential to greatly
reduce hemorrhagic side effect. A rat embolic model with an easy access of a magnet was …

In previously published studies, intra-arterial (ia), but not intravenous (iv) delivery of
recombinant tissue-type plasminogen activator (rtPA) immobilized on the surface of …

Recombinant tissue plasminogen activator (rtPA) is the only thrombolytic agent that has
been approved by the FDA for treatment of ischemic stroke. However, a high dose …

Background and methods Silica-coated magnetic nanoparticle (SiO2-MNP) prepared by the
sol-gel method was studied as a nanocarrier for targeted delivery of tissue plasminogen …

Ionic cross-linking of water-soluble chitosan with sodium tripolyphosphate in the presence of
recombinant tissue plasminogen activator (rtPA) and magnetite (Fe3O4) nanoparticles could …